AnaptysBio’s (ANAB) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Thursday,RTT News reports. They currently have a $42.00 price target on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the stock. UBS Group raised their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. cut their price objective on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a research report on Tuesday. HC Wainwright decreased their target price on AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Truist Financial lifted their price target on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Finally, Guggenheim increased their price objective on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

AnaptysBio Stock Down 3.4 %

Shares of AnaptysBio stock traded down $0.69 during trading on Thursday, reaching $19.48. 109,060 shares of the stock were exchanged, compared to its average volume of 348,333. The firm has a market cap of $592.78 million, a price-to-earnings ratio of -3.19 and a beta of -0.24. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $41.31. The stock’s fifty day moving average is $31.40 and its 200 day moving average is $29.89.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Equities analysts forecast that AnaptysBio will post -6.09 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. The trade was a 72.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at $595,440.66. This represents a 8.88 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,440 shares of company stock valued at $892,936. Insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds have recently added to or reduced their stakes in ANAB. Allspring Global Investments Holdings LLC purchased a new position in shares of AnaptysBio in the 1st quarter worth $38,000. Values First Advisors Inc. purchased a new position in AnaptysBio in the third quarter worth about $49,000. nVerses Capital LLC grew its stake in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the period. Headlands Technologies LLC increased its position in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 2,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.